A case of insulin allergy successfully managed using multihexamer-forming insulin degludec combined with liraglutide

Fujishiro M.; Izumida Y.; Takemiya S.; Kuwano Y.; Takamoto I.; Suzuki R.; Yamauchi T.; Ueki K.; Kadowaki T.

首页> 外文期刊>Diabetic medicine: A journal of the British Diabetic Association >A case of insulin allergy successfully managed using multihexamer-forming insulin degludec combined with liraglutide

【24h】

A case of insulin allergy successfully managed using multihexamer-forming insulin degludec combined with liraglutide

机译：使用形成多六聚体的地德格胰岛素联合利拉鲁肽成功治疗胰岛素过敏的病例

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundInsulin allergy, one of insulin's adverse effects, is rare, especially in patients with Type 2 diabetes, but management is difficult and no effective strategy has yet been established. We experienced an insulin allergy case successfully managed with a novel combination of insulins.

机译：背景技术胰岛素过敏是胰岛素的不良反应之一，很少见，特别是在2型糖尿病患者中，但治疗困难，尚未建立有效的策略。我们经历了使用新型胰岛素组合成功治疗胰岛素过敏的案例。

著录项

来源
《Diabetic medicine: A journal of the British Diabetic Association》 |2016年第11期|共4页
作者
Fujishiro M.; Izumida Y.; Takemiya S.; Kuwano Y.; Takamoto I.; Suzuki R.; Yamauchi T.; Ueki K.; Kadowaki T.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内分泌腺疾病及代谢病;
关键词

相似文献

外文文献
中文文献
专利

1. A case of insulin allergy successfully managed using multihexamer-forming insulin degludec combined with liraglutide [J] . Fujishiro M., Izumida Y., Takemiya S., Diabetic medicine: A journal of the British Diabetic Association . 2016,第11期

机译：使用形成多六聚体的地德格胰岛素联合利拉鲁肽成功治疗胰岛素过敏的病例
2. Superior HbA1c control with the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50?units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double‐blind, randomized trial [J] . Watada Hirotaka, Kaneko Shizuka, Komatsu Mitsuhisa, Diabetes, obesity & metabolism . 2019,第12期

机译：优质的HBA1C控制与胰岛素Degludec和Liraglutide（IDEGLIRA）的固定比例组合，与最大剂量为50岁？在第3期患有2型糖尿病的日本人中胰岛素Degludec的单位，双盲，随机试验
3. Insulin degludec/liraglutide ( ID ID egLira) maintains glycaemic control and improves clinical outcomes, regardless of pre‐trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin [J] . Meneghini L., Doshi A., Gouet D., Diabetic medicine: A journal of the British Diabetic Association . 2020,第2期

机译：胰岛素Degludec / Liraglutide（ID eglira）维持血糖控制并提高临床结果，无论预临时胰岛素剂量，在患有2型糖尿病的人的人上都是在基础胰岛素上不受控制的
4. Insulin Degludec, Insulin Glargine U300, and Other Novel Insulin Formulations [C] . American College of Veterinary Internal Medicine Forum Conference . 2018

机译：胰岛素Degludec，胰岛素甘氨酸U300等新型胰岛素配方
5. Evaluating Hypoglycemic Risk of Two Basal Insulin Delivery Methods for Type 1 Diabetes: A Comparison of Tresiba Insulin Against Continuous Subcutaneous Insulin Infusion Using Data from Continuous Glucose Monitors [D] . Lane, Benjamin. 2020

机译：评估1型糖尿病两种基础胰岛素递送方法的低血糖风险：使用来自连续葡萄糖监测器的数据进行TRESIBA胰岛素对连续皮下胰岛素输注的比较
6. Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi) Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications [O] . Carol H. Wysham, Carlos Campos, Davida Kruger 2018

机译：糖尿病未充分控制的糖尿病患者的胰岛素Degludec / Liraglutide（IDegLira）和胰岛素Glargine U100 / Lixisenatide（iGlarLixi）的安全性和有效性两种基础药物和一种胰高血糖素样肽1受体激动剂的新型共同制剂。降糖药
7. Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese patients with type 2 diabetes in a phase 3, open‐label, randomized trial [O] . Kohei Kaku, Eiichi Araki, Yukio Tanizawa, 2019

机译：与胰岛素Degludec和Liraglutide（IDEGLIRA）的胰岛素Degludec和Liraglutide在胰岛素-Naïve日本患者中的胰岛素Degludec和Liraglutide中的胰岛素-Naïve，在第3型糖尿病中，开放标签，随机试验

A case of insulin allergy successfully managed using multihexamer-forming insulin degludec combined with liraglutide

摘要

著录项

相似文献

相关主题

期刊订阅